Enzo Biochem Inc. (NYSE:ENZ) announced today that David Goldberg, Vice
President, Corporate Development, will speak on the Company’s extensive
oral immune regulation platform at the Windhover TA Partnerships
2009
conference in Boston, MA, on Wednesday, November 18, 2009, where Enzo’s
EGS21, an orally administered beta glucosylceramide formulation, now
undergoing clinical study, was named one of this year’s "top 10
inflammatory/autoimmune projects to watch.”
"This is a welcome recognition by a leading industry information
organization,” said Mr. Goldberg. "EGS21 is one of several formulations
derived from Enzo’s pioneering therapeutic platforms utilizing oral
immune regulation for immune mediated diseases. Our Enzo Therapeutics
subsidiary has long viewed oral immune regulation as an exciting and
promising platform, and it is one that we continue to pursue through
studies involving treatment candidates for unmet medical needs.”
Among the other projects based on this platform, Mr. Goldberg said, is
Alequel™, an individualized therapy for treatment of Crohn’s disease,
and Optiquel™, an oral, novel peptide for autoimmune uveitis, currently
involved in a proof of concept trial undertaken in conjunction with the
National Eye Institute.
In a report at the recent Liver Conference on clinical studies involving
EGS21, data was presented showing that oral administration of EGS21
appears to be safe and biologically active in patients with insulin
resistance and NASH (non-alcoholic steatohepatitis), a nonalcoholic
fatty liver disease that is the most common form of chronic liver
disease in the Western world.
The TA Partnership 2009 conference is sponsored by Windhover Information
Inc., part of Elsevier, the world’s leading publisher of science,
technical and health information. For 20 years Windhover Information has
been a major provider of analysis and commentary on health care business
strategy, industry deal making, marketplace trends, and the world of
medical start-ups.
About Enzo
Enzo Biochem is engaged in the research, development, manufacture and
licensing of innovative health care products and technologies based on
molecular biology and genetic engineering techniques, and in providing
diagnostic services to the medical community. Enzo’s Life Sciences
division develops, produces and markets proprietary labeling and
detection products for gene sequencing, genetic analysis and
immunological research among others. Its catalog of over 40,000
products serves the molecular biology, drug discovery and pathology
research markets. The Company's therapeutic division is in various
stages of clinical evaluation of its proprietary immune regulation
medicines for uveitis and Crohn's disease and conducts pre-clinical
research on several candidate compounds aimed at producing new mineral
and organic bone, including technology that could provide therapy for
osteoporosis and fractures, among other applications. Enzo’s Clinical
Labs division provides routine and esoteric reference laboratory
services for physicians in the New York Metropolitan and New Jersey
areas. Underpinning the Company’s technology and operations is an
extensive intellectual property estate in which Enzo owns or licenses
over 230 patents worldwide, and has pending applications for over 200
more. For more information visit the Company’s website www.enzo.com.
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.
